Do you want to read an article? Please log in or register.
Real-World Outcomes of FLAG-Ida Regimen in 1079 Adult Patients With First Relapsed/Refractory AML: A PETHEMA Study
Leukemia
Related content
Leukemia
Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With FLT3-Mutated AML: A FILO-DATAML-PETHEMA Real-World Study
Am J Hematol
Aspas Requena G, Montesinos P, Bérard E, Bertoli S, Rodríguez-Veiga R, Simand C, Torres L, Peterlin P, Tormo M, Birsen R, Bergua-Burgues JM, Tavernier E, Bernal Del Castillo T, Carré M, Gil C, Contejean A, Rodríguez-Arbolí E, Orvain C, Rodríguez-Medina C, Veronese L, Sayas Lloris MJ, Delabesse E, Serrano J, Mineur A, García-Fortes M, Guieze R, Amigo ML, Pigneux A, Algarra Algarra L, Recher C, Dumas PY, Martínez-Cuadrón D
doi: 10.1002/ajh.70233
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE study
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
ESMO Open
Peters S, Salomonsen RJ, Diaz Perez I, Shcherbakova T, Wang A, Cai L, Sadow S, Liu SV
doi: 10.1016/j.esmoop.2025.106031
Lymphoma
Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma
Blood
Crombie JL, Ahmed S, Frigault MJ, Hunter BD, Palomba ML, Mirza AS, Lunning MA, Egini O, Odstrcil Bobillo MS, Kallam A, Kambhampati Thiruvengadam S, Lee D, Dahiya S, Hamadani M, Herrera AF, Lee CJ, Patel K, Patel SS, Reagan PM, Shadman M, Bernasconi D, Kim S, Liu FF, Roy D, Pasquini MC, Isufi I
doi: 10.1182/blood.2025031733
Leukemia
Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients
Am J Hematol
Molica M, Miralles G, Dillon R, Annunziata M, Basheer F, Bergua JM, Calmet FV, Campbell V, Cetin D, Cimino G, Ciotti G, Corbingi A, De Fazio L, Erol HA, Federico V, Gil C, Gulu YM, Malcorra AB, Mariani S, Mazzone C, Mulè A, Musuraca G, Khan A, Norata M, O'Nions J, Palumbo FE, Papayannidis C, Piccioni AL, Rubio MTO, Sanchez-Tovar J, Serin I, Serrao A, Sevindik OG, Sucato G, Urbano MA, Vetro C, Vives S, Rossi M, Martelli MP, Montesinos P, Othman J, Perrone S
doi: 10.1002/ajh.70142
ELCC 2026
Lung, Respiratory and Thoracic Cancer
The Italian ATLAS registry study: Real-world outcomes with adjuvant osimertinib in patients with resected EGFR-mutated NSCLC
Lung, Respiratory and Thoracic Cancer
Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States
Adv Ther
Sankar K, Unni S, Eberl M, Le H, Herrmann T, Gorsh B, Tang M, Coerts F, Ahmed S
doi: 10.1007/s12325-025-03408-z
Lung, Respiratory and Thoracic Cancer
Survival outcomes of patients with uncommon EGFR mutations in surgically resected lung adenocarcinoma: A multi-institutional real-world database study (CReGYT-01 EGFR study)
Lung Cancer
Hayasaka K, Shimokawa M, Haratake N, Notsuda H, Katsumata S, Hamada A, Nomura K, Fujino K, Yoshikawa M, Suzawa K, Shien K, Suda K, Ohara S, Fukuda S, Kinoshita I, Takamori S, Muto S, Takanashi Y, Mizuno K, Hayakawa T, Sekihara K, Toda M, Matsuo S, Takegahara K, Hashimoto M, Nakahashi K, Endo M, Ozawa H, Fujikawa R, Tomioka Y, Namba K, Matsubara T, Suzuki J, Watanabe H, Takada K, Hoshino H, Kaiho T, Toyoda T, Shiono S, Soh J, Ohde Y, Okada Y
doi: 10.1016/j.lungcan.2026.108908
Lung, Respiratory and Thoracic Cancer
Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study
Lung Cancer
Gomez-Randulfe I, Monaca F, Cantale O, Reale ML, Mrak L, Zullo L, Diaz SS, Bueno MZ, Maridueña Moreno MA, Davis C, Cox S, Lee D, Shah R, Geldart T, Baena J, Benitez JC, Rosario Garcia Campelo MA, Remon J, Planchard D, Galetta D, Tiseo M, Cortinovis D, Metro G, Bria E, Passiglia F, Novello S, Califano R
doi: 10.1016/j.lungcan.2025.108797
Lymphoma
Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large Bcell lymphoma: real-world data from the EarlyMIND study
Haematologica
Brisou G, Paillassa J, Bernard S, Tournilhac O, Fornecker LM, Maloisel F, Gastaud L, Durot E, Tempescul A, Braun T, Ivanov V, Cherel B, Serrier C, Delage J, El Yamani A, Delapierre B, Lebras L, Lestang E, Villesuzanne C, Agape P, Escure G, Fouillet L, Nicol C, Olivier G, Levy A, Le Bris AS, Cassuto O, Jacquemelle L, Haioun C, Herbaux C
doi: 10.3324/haematol.2024.287141